Deloitte March 4, 2021
Asif Ahmed, Wendell Miranda, Brett Davis, Natasha Elsner

Digital medicine products are transforming research and care models, and changing regulations’ aim to expand access. Explore how organizations are aligning for success in the Future of Health™, where digital medicine products will be used at scale.

Executive summary

The last few years have witnessed a proliferation of digital medicine products, including digital therapeutics (i.e., regulated products that employ software to deliver evidence-based therapeutic interventions) and digital companions (i.e., products that provide additional services and insights for patients to improve their experience, knowledge, and outcomes of their existing drug therapy). The potential for their use in conjunction with or as an alternative to drug therapies has sparked interest among many companies, even outside of traditional health care and life sciences,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Govt Agencies, Healthcare System, Insurance, Medical Devices, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID, Technology
Pelago Defies Digital Health Funding Drought, Raises $58M
Digital health venture capital deals stagnate
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Embracing digital transformation with a digital factory
What Change Healthcare And The Postal Service Can Tell Us About The Coming Platform Revolution

Share This Article